VISION DMD · Project

Safer Steroid Alternative for Duchenne Muscular Dystrophy Entering Phase 2 Trials

healthTestedTRL 6

Boys with Duchenne muscular dystrophy gradually lose their ability to walk and move, and current steroid treatments — while they help slow this down — come with brutal side effects like weight gain, bone loss, and stunted growth. A team across 6 countries designed a new drug called VBP15 that works like a steroid but without most of those harmful side effects. They ran Phase 2 clinical trials to prove it's safe and effective in young boys who can still walk. The goal is to give these kids a treatment families can actually accept long-term, buying them more years of mobility and better quality of life.

By the numbers

6,000,000

EUR in EU funding for Phase 2 clinical trials

2100

drug months of cumulative patient exposure planned

consortium partners across the trial programme

countries involved in clinical trial delivery

SMEs participating in the consortium

The business problem

What needed solving

Current treatments for Duchenne muscular dystrophy rely on corticosteroids that cause severe side effects — weight gain, bone loss, behavioral changes, growth suppression — leading many families and clinicians worldwide to refuse or limit treatment. This means boys with DMD lose muscle function faster than necessary simply because the available medicine is too harmful to use at effective doses long-term. The pharmaceutical industry needs a drug that keeps the muscle-protecting benefits of steroids without the side effects that make them unacceptable.

The solution

What was built

The project completed Phase 2a and Phase 2b clinical trials of VBP15 (vamorolone), a steroid-like drug for DMD with reduced side effects, generating safety, tolerability, and efficacy data in ambulant boys. It also validated the Time to Stand Test as a primary endpoint and explored serum biomarkers and MRI techniques for monitoring muscle pathology.

Audience

Who needs this

Rare disease pharma companies seeking Phase 3-ready neuromuscular assetsCROs specializing in pediatric rare disease clinical trialsBiomarker and diagnostics companies focused on muscle diseasesPatient advocacy organizations funding DMD treatment developmentVenture capital firms investing in orphan drug pipelines

Business applications

Who can put this to work

Rare Disease Pharmaceuticals

enterprise

Target: Pharma companies with orphan drug portfolios or rare neuromuscular disease pipelines

If you are a rare disease pharma company looking to expand your neuromuscular portfolio — this project completed Phase 2 clinical trials of VBP15, an orphan drug for Duchenne muscular dystrophy with up to 2100 drug months of cumulative exposure data. The drug retains corticosteroid efficacy while reducing severe side effects, addressing the main barrier to treatment acceptance. Licensing or co-development could give you a Phase 3-ready asset in a market with enormous unmet need.

Clinical Research Organizations

mid-size

Target: CROs specializing in pediatric or rare disease trials

If you are a CRO with expertise in rare disease or pediatric clinical trials — this consortium built trial infrastructure across Europe and the US through networks like TREAT-NMD, CINRG, and ECRIN-ERIC. The project validated the Time to Stand Test as a primary endpoint and explored innovative serum biomarkers and MRI techniques for tracking muscle pathology. These validated methods and established trial sites could accelerate your own rare disease trial delivery.

Diagnostic and Biomarker Services

SME

Target: Companies developing biomarker assays or MRI-based diagnostic tools for muscle diseases

If you are a diagnostics company working on muscle disease assessment — this project explored serum biomarkers and wide-scale MRI techniques to measure drug effects on muscle cellular pathology in DMD patients. These tools were tested across a 10-partner consortium in 6 countries, generating real clinical validation data. Integrating these biomarker approaches into your diagnostic platform could open doors in the growing rare disease monitoring market.

Frequently asked

Quick answers

What would licensing or acquiring VBP15 cost?

The project received EUR 6,000,000 in EU funding for Phase 2 trials, with additional prior investment from government grants and international patient groups for preclinical and Phase 1 work. Licensing terms would need to be negotiated with the consortium, but the completed Phase 2 data package significantly de-risks the asset for any acquirer.

Can VBP15 production scale to meet global demand?

Based on available project data, VBP15 is a small-molecule drug designed for affordability, which typically means established manufacturing routes. The project explicitly aimed at 'an affordable therapy,' suggesting scalability was a design priority. However, specific manufacturing capacity details are not included in the project data.

What is the IP and licensing situation?

VBP15 has orphan drug designation, which provides market exclusivity incentives in both the EU and US. The consortium includes 3 SMEs and industrial partners who likely hold key IP. Specific licensing arrangements would need to be discussed with the coordinator at the University of Newcastle upon Tyne.

Where does VBP15 stand in the regulatory process?

The project completed Phase 2a (safety and tolerability of ascending doses) and Phase 2b (efficacy and safety of two doses) clinical trials, designed based on both FDA and EMA regulatory advice. Extension studies collected long-term safety data with up to 2100 drug months of cumulative exposure. This positions VBP15 for Phase 3 registration trials.

How long before this could reach patients?

The project ran from 2016 to 2021 and completed Phase 2 trials. Based on typical drug development timelines, Phase 3 trials and regulatory approval would still be required before market launch. The regulatory groundwork with both FDA and EMA has already been laid during this project.

Could VBP15 be combined with other DMD treatments?

The project objective explicitly states that VBP15 could 'potentially be used in combination with stratified therapies as they are developed.' This combinability is a significant commercial advantage as the DMD treatment landscape expands with gene therapies and other emerging approaches.

What clinical evidence supports the drug's advantage over current steroids?

Positive preclinical and Phase 1 results preceded this project. Phase 2 trials tested safety, tolerability, and efficacy in ambulant DMD boys, using the Time to Stand Test as a primary endpoint plus innovative serum biomarkers and MRI techniques. The key differentiator is retaining corticosteroid efficacy while reducing or eliminating the severe side effects that limit current treatment acceptance.

Consortium

Who built it

The 10-partner consortium spans 6 countries (CZ, FR, LU, NL, UK, US) with a 30% industry ratio — a strong mix for clinical drug development. The 3 SMEs bring specialized capabilities typical of rare disease drug development, while 4 research organizations and 2 universities provide the scientific backbone. The inclusion of US partners alongside European ones signals a dual-market regulatory strategy targeting both FDA and EMA approval. The consortium connects three major networks — TREAT-NMD (patient registry and standards), CINRG (clinical trial network), and ECRIN-ERIC (European clinical research infrastructure) — giving it reach far beyond its 10 formal partners.

UNIVERSITY OF NEWCASTLE UPON TYNECoordinator · UK
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORKparticipant · FR
LUXEMBOURG INSTITUTE OF HEALTHthirdparty · LU
Masarykova univerzitathirdparty · CZ
FAKULTNI NEMOCNICE MOTOL A HOMOLKAparticipant · CZ
CERATIUM LIMITEDparticipant · UK
STICHTING WORLD DUCHENNE ORGANIZATIONparticipant · NL

How to reach the team

University of Newcastle upon Tyne (UK) — search for the VISION DMD project lead in their Institute of Genetic Medicine or neuromuscular disease group

Order a report on this consortium See UNIVERSITY OF NEWCASTLE UPON TYNE profile →

Next steps

Talk to the team behind this work.

Want an introduction to the VISION DMD team to discuss licensing, co-development, or biomarker collaboration? SciTransfer can arrange a qualified meeting with the right people in the consortium.

Order a report on this topic More in Health & Biomedical